We are live on ! Find out more
PVLA icon

Palvella Therapeutics

41 hedge funds and large institutions have $6.92M invested in Palvella Therapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

0.78% less ownership

Funds ownership: 38.97% → 38.19% (-0.78%)

11% less funds holding

Funds holding: 46 → 41 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

73% less capital inflows, than outflows

Capital inflows: $171K | Capital outflows: $623K

Holders
41
Holders Change
-5
Holders Change %
-10.87%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PVLA Hedge Fund Activity: Q1 2024 in Review

41 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2024, worth a combined $6.92M — down 5.6% from $7.32M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PVLA and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 10 added.

The largest buyer was Renaissance Technologies, adding an estimated $63.5K. The largest seller was 1620 Investment Advisors, exiting entirely with an estimated $318K sold.

  • 41 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2024, down from 46 in Q4 2023.
  • Funds reported $6.92M of Palvella Therapeutics stock for Q1 2024, down 5.6% quarter-over-quarter.
  • 3 funds opened new Palvella Therapeutics positions in Q1 2024 and 8 closed out, a net change of -5 holders.
  • The largest Palvella Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $63.5K added.
  • The largest Palvella Therapeutics seller in Q1 2024 was 1620 Investment Advisors, an estimated $318K sold.

Based on aggregated 13F filings for Q1 2024.